Sun Pharma tanks 4% on reports USFDA issued notice on Halol plant

Phillips-Medisize's medical & clean room moulding facility
Extending losses for the fourth straight session, shares of Sun Pharma on Wednesday slipped over 4% on news report that US Food and Drug Administration has issued notice to the pharma major after having inspected its Halol unit in Gujarat.

Reacting to the development, the stock of the company fell as much as 4.50% on the BSE, and was the worst performing stock on Sensex. The stock has shed 7% in the last 4 days, including today. 

By afternoon, a total of 42 crore shares changed hands on the counter on BSE, compared with a two-week daily average of 6.79 lakh shares.

Meanwhile, the Exchange sought clarification from Sun Pharmaceutical with reference to ET NOW quoting "USFDA informs that Halol issued 14-page Form 483 post inspection".

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel